Jasper Therapeutics (JSPR)
NASDAQ:JSPR
Want to see JSPR full AI Analyst Report?
Total Valuation
Jasper Therapeutics has a market cap or net worth of $26.03M. The enterprise value is -$12.99M.
Market Cap$26.03M
Enterprise Value-$12.99M
Share Statistics
Jasper Therapeutics has 27,996,819 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding27,996,819
Owned by Insiders1.34%
Owned by Institutions0.05%
Financial Efficiency
Jasper Therapeutics’s return on equity (ROE) is -18.26 and return on invested capital (ROIC) is -338.11%.
Return on Equity (ROE)-18.26
Return on Assets (ROA)-2.12
Return on Invested Capital (ROIC)-338.11%
Return on Capital Employed (ROCE)-3.57
Revenue Per Employee0.00
Profits Per Employee-1.18M
Employee Count64
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Jasper Therapeutics is ―. Jasper Therapeutics’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio8.45
Price to Fair Value8.45
Price to FCF-0.45
Price to Operating Cash Flow-0.29
PEG Ratio0.02
Income Statement
In the last 12 months, Jasper Therapeutics had revenue of 0.00 and earned -75.80M in profits. Earnings per share was -3.95.
Revenue0.00
Gross Profit-1.06M
Operating Income-80.52M
Pretax Income-75.80M
Net Income-75.80M
EBITDA-82.83M
Earnings Per Share (EPS)-3.95
Cash Flow
In the last 12 months, operating cash flow was -54.68M and capital expenditures -7.00K, giving a free cash flow of -54.69M billion.
Operating Cash Flow-54.68M
Free Cash Flow-54.69M
Free Cash Flow per Share-1.95
Dividends & Yields
Jasper Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.39
52-Week Price Change-83.08%
50-Day Moving Average1.16
200-Day Moving Average2.06
Relative Strength Index (RSI)50.84
Average Volume (3m)399.98K
Important Dates
Jasper Therapeutics upcoming earnings date is May 8, 2026, After Close (Confirmed).
Last Earnings DateMar 30, 2026
Next Earnings DateMay 8, 2026
Ex-Dividend Date―
Financial Position
Jasper Therapeutics as a current ratio of 2.62, with Debt / Equity ratio of 29.75%
Current Ratio2.62
Quick Ratio2.62
Debt to Market Cap0.04
Net Debt to EBITDA0.33
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Jasper Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Jasper Therapeutics EV to EBITDA ratio is -0.09, with an EV/FCF ratio of -0.10.
EV to Sales0.00
EV to EBITDA-0.09
EV to Free Cash Flow-0.10
EV to Operating Cash Flow-0.10
Balance Sheet
Jasper Therapeutics has $28.69M in cash and marketable securities with $1.24M in debt, giving a net cash position of $27.46M billion.
Cash & Marketable Securities$28.69M
Total Debt$1.24M
Net Cash$27.46M
Net Cash Per Share$0.98
Tangible Book Value Per Share$0.22
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Jasper Therapeutics is $8.13, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.13
Price Target Upside696.57% Upside
Analyst ConsensusModerate Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast5.45%